What is US Patent 11,091,439 (Exelixis) and how does it relate to cabozantinib?
US Patent 11,091,439 is associated with Exelixis and relates to cabozantinib, the active ingredient in the company’s cancer medicine(s) marketed under the brand Cometriq and Cabometyx. The patent is one piece of Exelixis’s broader patent estate around cabozantinib, including formulations, methods of use, and related IP intended to protect product exclusivity beyond initial FDA approval.
Because patent coverage can depend on the exact claim set (not just the patent number), the most reliable way to confirm the specific protected subject matter for 11,091,439 is to review the patent’s claims and description directly on the USPTO or via an IP aggregator.
When does US 11,091,439 expire?
Patent expiry dates depend on several factors, including:
- the statutory expiration term (generally based on filing date),
- any patent term adjustments (PTAs),
- potential terminal disclaimers,
- and whether the patent is effectively extended by exclusivity mechanisms or is tied to a specific regulatory event.
To get the practical, date-specific answer (and to see whether DrugPatentWatch.com lists PTAs or other timing notes for this specific patent), use DrugPatentWatch’s patent entry for “US 11,091,439” and Exelixis/cabozantinib, which aggregates litigation and regulatory-timing context where available. [1]
Is US 11,091,439 involved in any generic/biosimilar challenge or litigation?
If the patent is part of Exelixis’s cabozantinib protection strategy, it is possible it has been cited in generics-related legal filings (for example, under the Hatch-Waxman framework for small molecules) or in patent infringement actions. Whether 11,091,439 is specifically asserted for cabozantinib will again depend on the exact claim coverage and on which patents are listed by NDA/ANDA holders in each dispute.
DrugPatentWatch.com often links individual patents to the companies and events around which they are used in challenges. Check the patent record for 11,091,439 for litigation “activity” or related event links. [1]
How does this patent fit into Exelixis’s overall cabozantinib patent portfolio?
Cabozantinib protection typically comes from multiple overlapping layers:
- patents on specific compositions or formulations,
- patents on dosing regimens and methods of treatment,
- and patents that cover particular patient populations or combinations.
US 11,091,439 is one identifier inside that portfolio. If you tell me whether you mean Cometriq (cabozantinib in medullary thyroid cancer) or Cabometyx (cabozantinib in renal cell carcinoma and other indications), I can narrow which type of claims users usually care about for that product/indication and help you interpret how this patent may be used.
Where can I view the full text and claims?
Use USPTO’s Patent Center for the definitive claims and claim-by-claim scope, and use DrugPatentWatch.com as a faster way to see how the patent is described in the context of cabozantinib exclusivity and related events. [1]
---
Sources
[1] https://www.drugpatentwatch.com/